Ra Capital Management, L.P. holds a focused book of 85 stocks worth $9.4B as of Q1 2026 (disclosed May 15, 2026, a ~45-day 13F lag). This quarter they opened Spyglass Pharma Inc and trimmed 4D Molecular Therapeutics In. Their largest long position is Ascendis Pharma A/s at 25% of the equity book.
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/1346824/holdings"
Use Arkolith to show RA CAPITAL MANAGEMENT, L.P.'s latest holdings, largest changes, and filing provenance.
Top-heavy: focused book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
75% mapped to company sectors
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices, no cost basis
Bars show each stock's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | Ascendis Pharma A/s - ADR SPONSORED ADR | $2.4B | 10.28M | 24.9% | —Held | |
| 2 | Vaxcyte Inc COMMON STOCK | $666.8M | 11.47M | 7.1% | ▲+7.0% Added · +750K sh | |
| 3 | Rhythm Pharmaceuticals Inc COMMON STOCK | $579.8M | 6.67M | 6.1% | —Held | |
| 4 | Tyra Biosciences Inc COMMON STOCK | $467.2M | 12.20M | 5.0% | —Held | |
| 5 | Sionna Therapeutics Inc COMMON STOCK | $397.1M | 9.91M | 4.2% | —Held | |
| 6 | Edgewise Therapeutics Inc COMMON STOCK | $328.5M | 10.43M | 3.5% | —Held | |
| 7 | Newamsterdam Pharma Co NV COMMON STOCK | $305.7M | 9.55M | 3.2% | —Held | |
| 8 | Nuvalent Inc-A COMMON STOCK | $259.6M | 2.53M | 2.8% | ▲+35% Added · +654K sh | |
| 9 | Dianthus Therapeutics Inc COMMON STOCK | $219.2M | 2.61M | 2.3% | ▲+62% Added · +1.0M sh | |
| 10 | Mineralys Therapeutics Inc COMMON STOCK | $208.4M | 7.69M | 2.2% | ▲+5.0% Added · +369K sh | |
| 11 | Spyglass Pharma Inc COMMON STOCK | $207.8M | 8.02M | 2.2% | ▲New New position | |
| 12 | Wave Life Sciences Ltd COMMON STOCK | $195.6M | 26.98M | 2.1% | ▲+48% Added · +8.8M sh | |
| 13 | Septerna Inc COMMON STOCK | $168.1M | 7.00M | 1.8% | —Held | |
| 14 | Disc Medicine Inc COMMON STOCK | $156.7M | 2.45M | 1.7% | ▲+24% Added · +474K sh | |
| 15 | Janux Therapeutics Inc COMMON STOCK | $155.5M | 11.19M | 1.6% | —Held | |
| 16 | Biocryst Pharmaceuticals Inc COMMON STOCK | $150.7M | 15.83M | 1.6% | —Held | |
| 17 | Bicara Therapeutics Inc COMMON STOCK | $144.3M | 7.26M | 1.5% | ▲+4.3% Added · +300K sh | |
| 18 | Praxis Precision Medicines I COMMON STOCK | $120.4M | 373.8K | 1.3% | —Held | |
| 19 | GH Research PLC COMMON STOCK | $107.9M | 7.68M | 1.1% | —Held | |
| 20 | Zai Lab Ltd-ADR COMMON STOCK | $107.4M | 5.71M | 1.1% | ▲New New position | |
| 21 | Taysha Gene Therapies Inc COMMON STOCK | $105.3M | 23.56M | 1.1% | —Held | |
| 22 | Vor Biopharma Inc COMMON STOCK | $96.4M | 5.40M | 1.0% | —Held | |
| 23 | Geron Corp COMMON STOCK | $95.0M | 63.77M | 1.0% | —Held | |
| 24 | Ars Pharmaceuticals Inc COMMON STOCK | $87.2M | 10.86M | 0.9% | —Held | |
| 25 | Sarepta Therapeutics Inc COMMON STOCK | $84.9M | 3.90M | 0.9% | ▲New New position | |
| 26 | Spyre Therapeutics Inc COMMON STOCK | $81.8M | 1.62M | 0.9% | —Held | |
| 27 | Evommune Inc COMMON STOCK | $80.3M | 3.49M | 0.9% | ▲+1.0% Added · +36K sh | |
| 28 | Climb Bio Inc COMMON STOCK | $77.4M | 11.30M | 0.8% | ▲+0.1% Added · +7K sh | |
| 29 | Solid Biosciences Inc COMMON STOCK | $67.2M | 9.34M | 0.7% | ▲+61% Added · +3.5M sh | |
| 30 | Artiva Biotherapeutics Inc COMMON STOCK | $63.5M | 9.85M | 0.7% | —Held | |
| 31 | Damora Therapeutics Inc COMMON STOCK | $62.1M | 2.40M | 0.7% | ▲New New position | |
| 32 | Xencor Inc COMMON STOCK | $59.1M | 4.90M | 0.6% | ▲New New position | |
| 33 | LB Pharmaceuticals Inc COMMON STOCK | $54.5M | 2.21M | 0.6% | —Held | |
| 34 | Jade Biosciences Inc COMMON STOCK | $51.6M | 3.67M | 0.5% | —Held | |
| 35 | Acumen Pharmaceuticals Inc COMMON STOCK | $49.5M | 20.99M | 0.5% | ▲+41% Added · +6.1M sh | |
| 36 | 4D Molecular Therapeutics In COMMON STOCK | $47.0M | 5.05M | 0.5% | ▼−11% Reduced · −603K sh | |
| 37 | Fulcrum Therapeutics Inc COMMON STOCK | $46.4M | 6.05M | 0.5% | —Held | |
| 38 | Capricor Therapeutics Inc COMMON STOCK | $45.8M | 1.51M | 0.5% | —Held | |
| 39 | Century Therapeutics Inc COMMON STOCK | $40.1M | 17.75M | 0.4% | ▲New New position | |
| 40 | Olema Pharmaceuticals Inc COMMON STOCK | $38.8M | 2.60M | 0.4% | —Held | |
| 41 | Lenz Therapeutics Inc COMMON STOCK | $38.2M | 4.18M | 0.4% | —Held | |
| 42 | Monopar Therapeutics Inc COMMON STOCK | $36.6M | 667.2K | 0.4% | —Held | |
| 43 | Pepgen Inc COMMON STOCK | $35.5M | 20.06M | 0.4% | —Held | |
| 44 | Design Therapeutics Inc COMMON STOCK | $31.6M | 2.97M | 0.3% | ▲+103% Added · +1.5M sh | |
| 45 | Mirum Pharmaceuticals Inc COMMON STOCK | $29.4M | 318.6K | 0.3% | ▲New New position | |
| 46 | Bioage Labs Inc COMMON STOCK | $28.9M | 1.65M | 0.3% | ▲New New position | |
| 47 | Lexeo Therapeutics Inc COMMON STOCK | $28.7M | 5.00M | 0.3% | —Held | |
| 48 | Assembly Biosciences Inc COMMON STOCK | $28.3M | 1.02M | 0.3% | —Held | |
| 49 | Rezolute Inc COMMON STOCK | $28.0M | 9.18M | 0.3% | —Held | |
| 50 | Aktis Oncology Inc COMMON STOCK | $26.9M | 1.50M | 0.3% | ▲New New position |
As-of date vs the date the SEC received each filing
| Quarter | As of | Filed | Positions | Value | Form |
|---|---|---|---|---|---|
| Q1 2026 | Mar 31, 2026 | May 15, 2026 | 86 | $9.4B | 13F-HR |
| Q4 2025 | Dec 31, 2025 | Feb 17, 2026 | 72 | $9.8B | 13F-HR |
| Q3 2025 | Sep 30, 2025 | Nov 14, 2025 | 68 | $8.1B | 13F-HR |
| Q2 2025 | Jun 30, 2025 | Aug 14, 2025 | 64 | $5.9B | 13F-HR |
| Q1 2025 | Mar 31, 2025 | May 15, 2025 | 86 | $6.0B | 13F-HR |
| Q4 2024 | Dec 31, 2024 | Feb 14, 2025 | 90 | $7.5B | 13F-HR |
| Q3 2024 | Sep 30, 2024 | Nov 14, 2024 | 82 | $8.7B | 13F-HR |
| Q2 2024 | Jun 30, 2024 | Aug 14, 2024 | 79 | $7.6B | 13F-HR |
| Q1 2024 | Mar 31, 2024 | May 17, 2024 | 76 | $7.9B | 13F-HR/A |
| Q4 2023 | Dec 31, 2023 | Feb 14, 2024 | 62 | $6.4B | 13F-HR |
| Q3 2023 | Sep 30, 2023 | Nov 15, 2023 | 66 | $5.1B | 13F-HR/A |
| Q2 2023 | Jun 30, 2023 | Aug 14, 2023 | 54 | $5.3B | 13F-HR |
| Q1 2023 | Mar 31, 2023 | May 15, 2023 | 59 | $4.4B | 13F-HR |
| Q4 2022 | Dec 31, 2022 | Feb 14, 2023 | 70 | $4.9B | 13F-HR |
| Q3 2022 | Sep 30, 2022 | Nov 14, 2022 | 81 | $4.7B | 13F-HR |
| Q2 2022 | Jun 30, 2022 | Aug 15, 2022 | 88 | $3.8B | 13F-HR |
| Q1 2022 | Mar 31, 2022 | May 16, 2022 | 96 | $4.6B | 13F-HR |
| Q4 2021 | Dec 31, 2021 | Feb 14, 2022 | 97 | $5.7B | 13F-HR |
| Q3 2021 | Sep 30, 2021 | Nov 15, 2021 | 95 | $7.2B | 13F-HR |
| Q2 2021 | Jun 30, 2021 | Aug 16, 2021 | 92 | $6.2B | 13F-HR |
| Q1 2021 | Mar 31, 2021 | May 17, 2021 | 82 | $6.6B | 13F-HR |
| Q4 2020 | Dec 31, 2020 | Feb 16, 2021 | 82 | $7.2B | 13F-HR |
Holdings from SEC EDGAR 13F-HR filings, updated quarterly ~45 days after quarter-end. Public domain. The book and weighting are long equity only; disclosed put/call options are listed separately and excluded from those totals. Price-derived performance is withheld until the price-source policy and freshness gate are green.